Representative Jefferson Shreve recently dipped into Vertex Pharmaceuticals stock, buying between $15,001 and $50,000 worth on March 13th. He revealed this transaction in a disclosure dated April 11th ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports.

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...